ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
US Tech 100
20,222.00
0.47%
Dow Jones
43,408.47
0.00%
Brent Oil
73.835
1.37%
Bitcoin
97,516.88
3.35%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Tango Therapeutics Inc (TNGX) Quote

Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

NASDAQ
4.08
0.23
(5.97%)
Closed November 20 4:00PM
Delayed by 15 minutes
4.07
-0.01
( -0.25% )
Pre Market: 8:56AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
4.07
Bid
3.95
Ask
4.24
Volume
395
0.00 Day's Range 0.00
2.70 52 Week Range 13.005
Market Cap
437.191M
Previous Close
4.08
Open
-
Last Trade
87
@
4.12
Last Trade Time
08:56:28
Financial Volume
-
VWAP
-
Average Volume (3m)
1,898,956
Shares Outstanding
107,417,818
Dividend Yield
-
PE Ratio
-4.31
Earnings Per Share (EPS)
-0.95
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.tangotx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was $4.08. Over the last year, Tango Therapeutics shares have traded in a share price range of $ 2.70 to $ 13.005.

Tango Therapeutics currently has 107,417,818 shares outstanding. The market capitalization of Tango Therapeutics is $438.26 million. Tango Therapeutics has a price to earnings ratio (PE ratio) of -4.31.

Ask ADVFN Intelligence (AI)

TNGX Latest News

More News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

17 hours ago
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

November 18 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

November 07 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

November 06 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration...

November 06 2024
Business Wire

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into...

November 06 2024
Business Wire

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

October 28 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

October 25 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.4211.50684931513.654.13913.530942283.88518512CS
4-2.11-34.1423948226.186.982.734210023.82922998CS
12-7.33-64.29824561411.411.922.718989565.57672376CS
26-3.56-46.65792922677.6312.0152.712715336.66445178CS
52-3.52-46.37681159427.5913.0052.79460837.57983127CS
156-7.84-65.827036104111.9113.032.476745727.40406089CS
260-5.54-57.64828303859.6118.842.476346227.60985813CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SPAISafe Pro Group Inc
$ 6.3796
(99.36%)
15.36M
WORXSCWorx Corporation
$ 1.72
(75.51%)
26.92M
CDTConduit Pharmaceuticals Inc
$ 0.1383
(49.84%)
176.39M
ESGROEnstar Group Ltd
$ 28.00
(40.92%)
29
CNSPCNS Pharmaceuticals Inc
$ 0.1689
(36.65%)
7.15M
WSBFWaterstone Financial Inc
$ 9.00
(-40.98%)
6
TRSTriMas Corporation
$ 15.62
(-40.79%)
11
PYXSPyxis Oncology Inc
$ 2.28
(-40.31%)
1.9M
BCAXBicara Therapeutics Inc
$ 11.00
(-40.15%)
316
XNCRXencor Inc
$ 15.11
(-36.30%)
43
CDTConduit Pharmaceuticals Inc
$ 0.1383
(49.84%)
176.39M
AKTSAkoustis Technologies Inc
$ 0.1175
(34.90%)
126.78M
PETWag Group Company
$ 0.2821
(34.27%)
28.19M
WORXSCWorx Corporation
$ 1.72
(75.51%)
26.92M
NVDANVIDIA Corporation
$ 148.10
(1.51%)
20.8M

TNGX Discussion

View Posts
Monksdream Monksdream 5 months ago
TNGX under $10
👍️0
Monksdream Monksdream 7 months ago
TNGX under $10
👍️0
bikaver bikaver 1 year ago
Stopped out with small loss.
👍️0
bikaver bikaver 1 year ago
TNGX......Holding up well, but will tumble soon.
👍️0
bikaver bikaver 1 year ago
TNGA.....short @ 8.60 This is the strength that I wanted to see!
👍️0
bikaver bikaver 1 year ago
TNGX.....Studying the TNGX chart this evening. I'll short it at a good sign of strength if the opportunity presents itself tomorrow.
👍️0
SmokeSignals SmokeSignals 1 year ago
up $4>H.C. Wainwright Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Barclays Releases a Buy Rating on Tango Therapeutics (TNGX)AUGUST 8, 2023TIPRANKS
Goldman Sachs Keeps Their Buy Rating on Tango Therapeutics (TNGX)AUGUST 7, 2023TIPRANKS
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsAUGUST 7, 2023TIPRANKS
Tango Therapeutics reports Q2 EPS (23c), consensus (34c)AUGUST 7, 2023TIPRANKS
👍️0

Your Recent History

NASDAQ
TNGX
Tango Therapeutics
NASDAQ
AZTA
Azenta
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved